Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Townson, Jason L Program Director/Principal Investigator (Last, First, Middle): BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Jason L Townson Postdoctoral Fellow P30 Role: Associate Member Cancer Therapeutics: Technology, Discovery & Targeted Delivery eRA COMMONS USER NAME (credential, e.g., agency login) jtownson EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) DEGREE INSTITUTION AND LOCATION MM/YY FIELD OF STUDY (if applicable) Queen's University, Kingston, Ontario, Canada University of Western Ontario, London, Canada University of New Mexico, Albuquerque BScH PhD 05/01 11/09 Postdoc 12/13 Life Sciences Medical Biophysics Nanomedicine and Cancer Biology A. Personal Statement The overall goal of my research is to better understand the interface between engineered materials and biological systems, with a primary focus on development of nanoparticles for imaging and therapeutic use in cancer. My graduate research in a cancer metastasis laboratory has provided me with significant experience with cancer cell culture (2D and 3D), animal models of metastatic cancer (xenografts and syngenic models) as well as multiple imaging modalities including MRI, in vivo video microscopy and ultrasound. All models and techniques were learned in the context of evaluating treatment efficacy of novel therapies for metastatic disease, with a primary focus on liver metastasis. As a postdoctoral fellow I applied my knowledge and experience with complex biological systems, in conjunction with my more recent research training in nanomaterials synthesis and characterization, in order to conduct experiments to quantify biodistribution, toxicity and therapeutic efficacy of nanoparticles in vivo as well as develop novel biomaterials. My research continues to focus on better understanding the complex interactions between nanoparticles and diverse cell populations in vivo in order to better optimize these particles as in vivo vectors for imaging and therapeutic cargo. B. Positions and Honors Positions and Employment 2002-2009 Graduate Student, Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada 2010-2013 Postdoctoral Fellow, University of New Mexico, Center for Micro-engineered Materials, Albuquerque, NM, USA 2014Research Assistant Professor, University of New Mexico, Department of Internal Medicine, Division of Molecular Medicine Honors 2003-2005 2004-2005 2005-2008 2008 2008 2009 Breast Cancer Research Society of Canada Studentship Ontario Graduate Scholarship Canadian Institute of Health Research - Doctoral Research Award Top poster - London Regional Cancer Program - Oncology Research and Education Day Travel Award - Graduate Program in Molecular Imaging Research Award 2009 World Molecular Imaging Congress - Student Travel Award PHS 398/2590 (Rev. 06/09) Page Biographical Sketch Format Page Townson, Jason L Program Director/Principal Investigator (Last, First, Middle): 2010-2012 Fellowship - The New Mexico Cancer Nanoscience and Microsystems Training Center (CNTC) 2011 Selected as participant at 2011 National Cancer Institute Cancer Research Imaging Camp 2012-2013 Junior Investigator Award - Gabrielle’s Angel Foundation Professional Memberships: 2011-Present American Association of Cancer Research, Associate member 2013-Present Materials Research Society C. Selected Publications: 1. Townson JL, Lin YS, Agola JO, Carnes EC, Leong HS, Lewis JD, Haynes C and Brinker CJ. Re- examining the Size/Charge Paradigm: Differing In Vivo Characteristics of Size and Charge-Matched Mesoporous Silica Nanoparticles. J Am Chem Soc. 2013 Oct;135:16030-3. PMCID:PMC3946529 2. Kaehr B, Townson JL, Kalinich RM, Awad Y, Swartzentruber BS, Dunphy DR and Brinker CJ. Cellular complexity captured in durable silica biocomposites. Proc Natl Acad Sci USA. 2012 Oct 23;109:17336-41. PMCID: PMC3491527 3. Ashley CE, Carnes EC, Epler KE, Padilla DP, Phillips GK, Castillo RE, Wilkinson DC, Wilkinson BS, Burgard CA, Kalinich RM, Townson JL, Chackerian B, Willman CL, Peabody DS, Wharton W and Brinker CJ. Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano. 2012 Mar 27;6(3):2174-88. PMCID:PMC3332089 4. Townson, JL, Ramadan SS, Simedrea C, Rutt BK, MacDonald IC, Foster PJ, Chambers AF (2009). ThreeDimensional imaging and quantification of both solitary cells and metastases in whole mouse liver by magnetic resonance imaging. Cancer Research 69:8326-8331. 5. Townson JL, MacDonald IC, Liby KT, MacKenzie L, Dales DW, Hedley BD, Foster PJ, Sporn MB, Chambers AF (2011). The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clin Exp Metastasis. 2011 Mar;28:309-17 6. Epler K, Padilla D, Phillips G, Crowder P, Castillo R, Wilkinson D, Wilkinson B, Burgard C, Kalinich R, Townson J, Chackerian B, Willman C, Peabody D, Wharton W, Brinker CJ, Ashley C and Carnes E. Targeted Delivery of Protein Toxins: Delivery of Ricin Toxin A-Chain by Peptide-Targeted Mesoporous Silica nanoparticle-Supported Lipid Bilayers. Adv Healthcare Mater. 2012 May; 1:348-53. 7. Brackstone M, Townson JL and Chambers AF (2007). Tumour dormancy in breast cancer: an update. Breast Cancer Research 9:208. PMCID: PMC1929094 8. Townson JL and Chambers AF (2006). Dormancy of solitary metastatic cells. Cell Cycle 5: 1744-1750 9. Townson JL, Naumov GN and Chambers AF (2003). The role of apoptosis in tumor progression and metastasis. Curr Mol Med 3:631-42 10.Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC and Chambers AF (2003). Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat. 2003 Dec;82(3):199-206. D. Research Support ONGOING 1 U01 CA151792-04 Willman, Brinker, PIs NIH-NCI PHS 398/2590 (Rev. 06/09) 10/1/2010 – 8/31/2015 Page Continuation Format Page Townson, Jason L Program Director/Principal Investigator (Last, First, Middle): Peptide-directed Protocells and Virus-Like Particles – new nanoparticle platforms for targeted delivery of multicomponent drugs The goal of the project is to develop nanoparticle platforms to target delivery of multiple different cargos to cancer cells. Role: Key personnel FA 9550-14-1-0066 Brinker, PI 2/1/2014 – 1/31/2017 Air Force Office of Scientific Research, AFOSR Biocompatible and Biomimetic Self-Assembly of Functional Nanostructures The major goal of this project is the discovery and integration of new classes of hybrid materials and devices displaying a symbiotic relationship between the biotic and abiotic components: Role: Key Collaborator LLS 7010-14 SCOR Carroll, NYU,PI; Willman, UNM, project PI 10/1/13 – 9/30/18 Lymphoma Leukemia Society Developing Novel Therapies for Pediatric and Young Adult ALL Silica nanoparticles have recently received FDA approval for targeted molecular imaging in cancer; these studies will lay the foundation for FDA-reviewed IND-directed toxicology studies. Role: Key personnel UNM-Alpine Biosciences Sponsored Research Agreement Brinker, PI Alpine Biosciences Development of protocells as nucleic acid delivery vehicle for a wide range of diseases Role: Co-Investigator COMPLETED Young Investigator Award Townson, PI 6/20/12-6/19/13 Gabriel’s Angels Foundation In Vivo Models for Design and Optimization of Targeted Nanocarriers (Protocells) for Leukemia Therapy The goal of this research is to assist in development of a nanoparticle optimized to reduce treatment toxicity while eliminating otherwise drug resistant leukemia cell populations. PHS 398/2590 (Rev. 06/09) Page Continuation Format Page